EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders

This trial is testing a specialized cell therapy called EBV-AST cells — immune cells grown in the lab that are trained to attack tumors driven by the Epstein-Barr virus (EBV), a common virus that in rare cases can cause serious blood cancers. The therapy is being tested in patients with EBV-associated lymphoproliferative disorders that have not responded to standard treatment. **You may be eligible if:** - You are between 18 and 75 years old - You have been diagnosed with an EBV-associated lymphoproliferative disorder (including EBV-positive DLBCL, NK/T-cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma, or post-transplant lymphoproliferative disease) that is relapsed or refractory after prior treatment - Your HLA type matches at least one of the specific markers used in this therapy (HLA-A02:01, HLA-A11:01, or HLA-A*24:02) - You are in reasonably good functional health (Karnofsky score ≥70) - Your life expectancy is at least 3 months **You may NOT be eligible if:** - You have active and uncontrolled graft-versus-host disease (for transplant patients) - You have a known allergy to the cell product - You have inadequate organ or bone marrow function - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.